April 26, 2024

News Collective

Complete New Zealand News World

Pharmaceutical companies are asking the government to invest more in health

Pharmaceutical companies are asking the government to invest more in health

Mexico City /

Pharmaceutical and medical device companies in Mexico They have asked the government to speed up its operations as well as increase investment in the health sector.

Humberto IsidoroDirector general change for Latin americaHe commented that there should be more capital injections by the federal administration given the growth of some chronic conditions such as cancer.

“There should be a little more budget from the government for health, especially for radiotherapy,” he said. Millennium.

In 2021, The investment in the infrastructure of the health sector amounted to 15,880 million pesos, 29.4 percent lower than the previous year; According to the figures of the Ministry of Finance and Public Credit.

Isidore He explained that most of the linear accelerators (used in radiotherapy) in the country are very old. Some of these products have been returned after 15 years of use in the United States.

“There are countries that have more technology-friendly policies, such as Chili pepper s Brazil, who introduced the largest team expansion program. There are also examples in Colombia“Calculate.

Alexander Paoliniboss Siemens Healtheners For Mexico, Central America and the Caribbean, he noted, the government must understand that health policy necessarily needs to invest in infrastructure.

“We are working on providing the facilities, the problem is that they have the budget and in Mexico It is not appropriate or necessary to address this situation. Because if we look at the installed base number, we will look like we are not that bad, but there are very few modern and effective devices,” noted the head of Mexican Association of Innovative Industries for Medical Devices (AMID).

The Mexican Association of Radiation Therapistsindicates that there are 162 radiotherapy teams in the country, i.e. 1.19 per million inhabitants.

See also  "The Nightmare": the other variant of Omicron that torments doctors and scientists

secondly, Fernando Cruz president Novartis MexicoAnother outstanding problem, he commented at a workshop, is that approval processes for clinical research are faster.

“There are areas of opportunity that we can work on with the authority; in particular, the process we have to approve for clinical research can be significantly reduced. Worldwide, the standard is 40 days or less, in Mexico this process takes more than 90 days to get That regulatory approval,” he explained.